SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
WEST LAFAYETTE, March 05, 2018 -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , today announced that the company’s management team will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12th at 2:50 p.m. EDT.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
